Try our Advanced Search for more refined results

In re HIV Antitrust Litigation

Track this case

Case Number:

3:19-cv-02573

See also:

Court:

California Northern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action

Judge:

Edward M Chen

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 27, 2023

    HIV Drug Buyers Urge $3.6B Verdict Against Gilead And Teva

    Gilead and Teva "cut a pay-off deal" to keep prices for two HIV drugs as "expensive as possible for as long as possible" and should be ordered to return overcharges totaling $3.6 billion, a lawyer for drug purchasers said Tuesday at the conclusion of a California federal antitrust trial.

  2. June 26, 2023

    Gilead Didn't Pay Teva In HIV Drug IP Deal, Economist Says

    An economics expert for Gilead and Teva, testifying Monday in a federal antitrust trial over claims the pharmaceutical giants struck an illegal "pay for delay" patent deal over two HIV medications, said a settlement provision allowing Teva to enter the market six months ahead of other generics had no value.

  3. June 23, 2023

    Ex-FTC Official Pans Claim Gilead-Teva Deal Hurt Competition

    California federal jurors considering claims that pharmaceutical companies Gilead Sciences Inc. and Teva Pharmaceutical Industries Ltd. reached an illegal agreement to delay generic versions of HIV medications heard from a former Federal Trade Commission economist on Friday, who disagreed that the deal stifled competition, noting that Gilead faced ongoing innovation from other drugmakers before its agreement with Teva.

  4. June 23, 2023

    Icon Ken Feinberg Shares Lessons From A Life Mediating

    With a high-profile antitrust trial underway in California federal court over claims Gilead and Teva illegally delayed generic competition for two HIV medications, mediation powerhouse Kenneth Feinberg is staying by the phone in Martha's Vineyard, ready to help shepherd the remaining litigants toward a resolution.

  5. June 21, 2023

    Ex-Jurist's $1,550-Hour Gilead Witness Job Not Ethics Issue

    A California federal judge overseeing an antitrust trial over claims Gilead Sciences Inc. and Teva Pharmaceuticals illegally delayed generic versions of two HIV medications refused Wednesday to let the plaintiffs question the ethics of a retired federal judge and current Irell & Manella LLP attorney who testified on the defendants' behalf as a $1,550-an-hour expert witness.

  6. June 20, 2023

    Gilead-Teva Deal Costs To Buyers Top $3.6B As Plaintiffs Rest

    Health care companies and health plans called their final witnesses Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal over two HIV medications, resting their case with testimony that brought their total claimed damages to more than $3.6 billion.

  7. June 16, 2023

    Harvard Profs Battle Over $1.5B Antitrust Damages Estimate

    A Harvard University professor emeritus testifying in a federal antitrust trial Friday over claims Gilead and Teva illegally delayed generic versions of HIV medications told a California jury that the suit's end-payor classes were overcharged $1.5 billion — provoking Gilead to challenge that amount at cross-examination using opinions from its own Harvard expert.

  8. June 14, 2023

    Ex-FDA Official Tells Antitrust Jury Generic Rivals Were Ready

    A former FDA official took the stand Wednesday in a federal antitrust trial over claims Gilead struck a deal with Teva to illegally delay generic versions of its blockbuster HIV medications until 2020, testifying that several generics manufacturers were ready to launch their versions in early 2018.

  9. June 13, 2023

    Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told

    A retired Harvard Medical School health economics professor testified Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal over two HIV medications, saying the agreement "delayed competition and imposed massive harms on purchasers," costing them over $2 billion.

  10. June 09, 2023

    Gilead-Teva IP Deal Struck Despite Invalidity Issues, Jury Told

    Two experts took the stand Friday on behalf of indirect drug buyers in a California federal antitrust trial over claims Teva struck an illegal "pay for delay" patent deal with Gilead over two HIV medications, testifying that Gilead's patents covered obvious technology and Teva knew that before entering the deal.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!